Eltrombopag PfOS
PreclinicalSmall molecule
NovartisEltrombopag PfOS is one of 4 small molecule programs targeting Primary Immune Thrombocytopenia (ITP). It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Primary Immune Thrombocytopenia (ITP)
#DrugCompanyPhaseTrials
1Promacta
GSKPhase 2
Ianalumab
NovartisPhase 2
Thrombopoietin Receptor Agonist
NovartisPhase 2
Eltrombopag PfOS
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Thrombocytopenic Purpura1 trial
Primary Immune Thrombocytopenia (ITP)1 trial
Drug Switching Strategy Study After rhTPO Second-Line Treatment Failure in ITP: A Randomized Controlled Trial Comparing High-Dose rhTPO Versus Eltrombopag
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Preclinical·NCT07476846·112 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Eltrombopag PfOS. EMBL-EBI & Wellcome Sanger Institute.
- [4]